And we think those data will be highly differentiated and highly compelling for physicians and patients across the population. Jeff, do you want to talk a little bit about the kind of frequency of interactions between physicians and patients?
Jeff Castelli: Yes, thanks, Brad and thanks Ellie. So physicians, typically will atleast see their patients every six months or a pretty comprehensive assessment. Obviously, it depends if they’re getting infusions at the clinic, they may or may not see them more regularly, if they’re the ones doing the infusions. But that larger workout every six months, is really when they get a sense of how the patients are doing from the last kind of comprehensive exam they had. So as Brad mentioned you know, is patient or physicians and patients are thinking about treatment changes, if they’ve started a new treatment, they probably would go about 12 months before they make the final kind of call or first call on whether they’re doing well enough and might consider a new treatment.
But, as we’ve seen, at least in the U.S. many of the patients from the next design studies that have switched to been on that treatment now for much over a year. So I think there’s certainly an opportunity we expect from a labeling perspective, from a potential need perspective to have switches from both of the products that are available currently.
Ellie Merle: And Sébastien, maybe just give us a color for some of the distribution of recorded sales of the product.
Sébastien Martel: Yes, Ellie, just add that as we look at to, to the last quarterly sales reported by Sanofi, looking at the speed within miles on the Nexviazyme, the vast majority of sales continue to be on miles on 77% for the fourth quarter on a global basis. Outside of the U.S., this is actually a lot higher than that 93% of sales were coming from myozyme, rest of world was 85%. And in the U.S. to 60% also feel coming from myozyme. So the majority of patients by the time we launch will likely still be on myozyme. I think the switch data that we have bodes well for switch quality weeks.
Ellie Merle: Thanks, Sébastien.
Sébastien Martel: Thank you, Ellie. Anything else?
Ellie Merle: Perfect. Thanks for that.
Operator: One moment for our next question. And our next question comes from Joseph Schwartz of SVB Securities. Your line is open.
Joseph Schwartz: Hi, thanks for the update. I was wondering if you could comment on your Pombiliti launch readiness in terms of manufacturing supply? How much are you accruing? And is there any reason that any of the supply you’re building ahead of the launch should not be used? And what’s your strategy for continuing to build supply?
Bradley Campbell: Yes, thanks for the question. So we have I think, prudently continued to manufacture AT-GAA and I think we noted last year in our financials, and Daphne highlighted quite a bit of an investment there. So we’re on track to have significant supply for all of our anticipated launches, we feel really good about that. We typically move products into, country in advance. And so with the positive progress in Europe, I think we’ve talked about now being able to start the process of release testing around Pombiliti, which is the ERT there. And then likewise, in United States, we’ve actually begun to move products here as well. So we feel really good about launch inventory. Our overall supply strategy I think we’ve described before which is we have plenty of capacity and supply coming out of China to support the first, year or two of launch.
